Cancers, Vol. 16, Pages 1598: No Racial Disparities Observed Using Point-of-Care Genetic Counseling and Testing for Endometrial and Ovarian Cancer in a Diverse Patient Population: A Retrospective Cohort Study
gaux J. Kanis
We investigated genetic counseling and testing rates for patients with gynecologic malignancy at a tertiary care center with a large minority population. Our retrospective cohort included newly diagnosed epithelial ovarian, fallopian tube, peritoneal, or endometrial cancer patients between January 2014 and June 2022. For endometrial cancer, 373 patients were identified. A total of 207 (55%) patients were screened using mismatch repair immunohistochemistry (MMR IHC). A total of 82 (40%) had MMR deficiencies on IHC. Of these, 63 (77%) received genetic counseling. A total of 62 (98%) underwent genetic testin...
Source: Cancers - April 22, 2024 Category: Cancer & Oncology Authors: Michael Kim Judy Hayek Cheyenne Acker Anjile An Peilin Zhang Constantine Gorelick Margaux J. Kanis Tags: Article Source Type: research
The karyometric signature is altered in fallopian tubes with serous tubal intraepithelial carcinoma
CONCLUSION: These data demonstrate an abnormal karyometric signature in STICs that may extend beyond the STIC, potentially providing an opportunity for early detection of fallopian tube neoplasia.PMID:38640774 | DOI:10.1016/j.ygyno.2024.04.007 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 19, 2024 Category: Cancer & Oncology Authors: Gustavo C Rodriguez Michael Yozwiak Omar L Nelson Hao Helen Zhang Ahyoung Amy Kim William Watkin Jennifer K Barton David S Alberts Source Type: research
The karyometric signature is altered in fallopian tubes with serous tubal intraepithelial carcinoma
CONCLUSION: These data demonstrate an abnormal karyometric signature in STICs that may extend beyond the STIC, potentially providing an opportunity for early detection of fallopian tube neoplasia.PMID:38640774 | DOI:10.1016/j.ygyno.2024.04.007 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 19, 2024 Category: Cancer & Oncology Authors: Gustavo C Rodriguez Michael Yozwiak Omar L Nelson Hao Helen Zhang Ahyoung Amy Kim William Watkin Jennifer K Barton David S Alberts Source Type: research
Cancers, Vol. 16, Pages 1560: A Perspective Review: Analyzing Collagen Alterations in Ovarian Cancer by High-Resolution Optical Microscopy
gnola
High-grade serous ovarian cancer (HGSOC) is the predominant subtype of ovarian cancer (OC), occurring in more than 80% of patients diagnosed with this malignancy. Histological and genetic analysis have confirmed the secretory epithelial of the fallopian tube (FT) as a major site of origin of HGSOC. Although there have been significant strides in our understanding of this disease, early stage detection and diagnosis are still rare. Current clinical imaging modalities lack the ability to detect early stage pathogenesis in the fallopian tubes and the ovaries. However, there are several microscopic imaging techniques...
Source: Cancers - April 19, 2024 Category: Cancer & Oncology Authors: Kristal L. Gant Manish S. Patankar Paul J. Campagnola Tags: Review Source Type: research
Rates of paclitaxel hypersensitivity reactions using a modified Markman’s infusion protocol as primary prophylaxis
ConclusionThe modified Markman ’s desensitisation protocol as primary prophylaxis did not reduce the rate or severity of paclitaxel hypersensitivity reactions, although all patients could be successfully rechallenged. (Source: Supportive Care in Cancer)
Source: Supportive Care in Cancer - April 17, 2024 Category: Cancer & Oncology Source Type: research
Has time to chemotherapy from primary debulking surgery in advanced ovarian cancer an impact on survival? - A population-based nationwide SweGCG study
CONCLUSIONS: For the entire cohort, stage IV, non-serous morphology and residual disease, but not TTC, influenced 5-year relative survival. However, longer TTC was associated with a poorer 2-year survival for those without residual disease after PDS.PMID:38603954 | DOI:10.1016/j.ygyno.2024.03.011 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 11, 2024 Category: Cancer & Oncology Authors: Pernilla Dahm-K ähler Angelique Fl öter Rådestad Erik Holmberg Christer Borgfeldt Maria Bjurberg Camilla Sk öld Kristina Hellman Preben Kj ølhede Karin St ålberg Elisabeth Åvall-Lundqvist Source Type: research
Has time to chemotherapy from primary debulking surgery in advanced ovarian cancer an impact on survival? - A population-based nationwide SweGCG study
CONCLUSIONS: For the entire cohort, stage IV, non-serous morphology and residual disease, but not TTC, influenced 5-year relative survival. However, longer TTC was associated with a poorer 2-year survival for those without residual disease after PDS.PMID:38603954 | DOI:10.1016/j.ygyno.2024.03.011 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 11, 2024 Category: Cancer & Oncology Authors: Pernilla Dahm-K ähler Angelique Fl öter Rådestad Erik Holmberg Christer Borgfeldt Maria Bjurberg Camilla Sk öld Kristina Hellman Preben Kj ølhede Karin St ålberg Elisabeth Åvall-Lundqvist Source Type: research
Has time to chemotherapy from primary debulking surgery in advanced ovarian cancer an impact on survival? - A population-based nationwide SweGCG study
CONCLUSIONS: For the entire cohort, stage IV, non-serous morphology and residual disease, but not TTC, influenced 5-year relative survival. However, longer TTC was associated with a poorer 2-year survival for those without residual disease after PDS.PMID:38603954 | DOI:10.1016/j.ygyno.2024.03.011 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 11, 2024 Category: Cancer & Oncology Authors: Pernilla Dahm-K ähler Angelique Fl öter Rådestad Erik Holmberg Christer Borgfeldt Maria Bjurberg Camilla Sk öld Kristina Hellman Preben Kj ølhede Karin St ålberg Elisabeth Åvall-Lundqvist Source Type: research
Identification of long noncoding RNAs downregulated specifically in ovarian high-grade serous carcinoma
CONCLUSION: We identified eleven lncRNAs that were specifically downregulated in HGSC. Of these, CBR3-AS1, NBR2, and ADAMTS9-AS2 had unique functions in the malignant behaviors of HGSC.PMID:38571514 | PMC:PMC10988898 | DOI:10.1002/rmb2.12572 (Source: Reproductive Biology)
Source: Reproductive Biology - April 4, 2024 Category: Reproduction Medicine Authors: Maki Hayashi-Okada Shun Sato Kengo Nakashima Takahiro Sakai Tetsuro Tamehisa Takuya Kajimura Isao Tamura Kotaro Sueoka Norihiro Sugino Source Type: research
Identification of long noncoding RNAs downregulated specifically in ovarian high-grade serous carcinoma
CONCLUSION: We identified eleven lncRNAs that were specifically downregulated in HGSC. Of these, CBR3-AS1, NBR2, and ADAMTS9-AS2 had unique functions in the malignant behaviors of HGSC.PMID:38571514 | PMC:PMC10988898 | DOI:10.1002/rmb2.12572 (Source: Reproductive Biology)
Source: Reproductive Biology - April 4, 2024 Category: Reproduction Medicine Authors: Maki Hayashi-Okada Shun Sato Kengo Nakashima Takahiro Sakai Tetsuro Tamehisa Takuya Kajimura Isao Tamura Kotaro Sueoka Norihiro Sugino Source Type: research
Ovarian Cancer in the Older Manitoban Population-Treatment Tolerance and Cancer-Related Outcomes: A Manitoba Ovarian Cancer Outcomes (MOCO) Group Study
CONCLUSIONS: Our study demonstrated a high rate of chemotherapy dose reduction and discontinuation in the elderly epithelial ovarian cancer population. Further research is needed to identify risk factors for treatment discontinuation and intolerance in this population.PMID:38534935 | DOI:10.3390/curroncol31030102 (Source: Current Oncology)
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Lesley F Roberts Pascal Lambert Mark W Nachtigal Alon D Altman Erin Dean Source Type: research
Ovarian Cancer in the Older Manitoban Population-Treatment Tolerance and Cancer-Related Outcomes: A Manitoba Ovarian Cancer Outcomes (MOCO) Group Study
CONCLUSIONS: Our study demonstrated a high rate of chemotherapy dose reduction and discontinuation in the elderly epithelial ovarian cancer population. Further research is needed to identify risk factors for treatment discontinuation and intolerance in this population.PMID:38534935 | PMC:PMC10969362 | DOI:10.3390/curroncol31030102 (Source: Current Oncology)
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Lesley F Roberts Pascal Lambert Mark W Nachtigal Alon D Altman Erin Dean Source Type: research
